Cosmo Pharmaceuticals Nv · SIX:COPN
Cosmo Pharmaceuticals Nv — H1 2023 Earnings Presentation
33 slides from Cosmo Pharmaceuticals Nv's earnings presentation, Jul 26, 2023
Slide 1: An Update On Our Progress: Half-Year Results 2023
An Update On Our Progress Half-Year Results 2023 July 26, 2023 1
Slide 2: Safe harbour
Safe harbour This presentation may include forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that any of its p
Slide 3: Contents
Contents 01 Investment strengths 04 An exciting R&D pipeline 02 H1 2023 financial & operational highlights 05 Key priorities and 2023 guidance 03 Two key growth drivers 3 July 2023
Slide 4: Investment strengths
01 Investment strengths 4 July 2023
Slide 5: Investment strengths
Investment strengths Growing revenue stream from an established business Two revolutionary growth drivers launched in large markets and entrusted to world-class partners Exciting development pipeline full of catalysts Strong financial position with no debt Profitable with dividends distributed in 20
Slide 6: Our main focus areas
Our main focus areas Gastroenterology HealthTech Dermatology 6 July 2023
Slide 7: Our product portfolio shows the breadth of our offering
Our product portfolio shows the breadth of our offering Established portfolio Growth drivers Pipeline CB-03-10 solid tumors (Cortexolone 17α-valerate-21-propionate) CB-01-33 Bile Acid Diarrhea (Colesevelam) Additional features & apps under development Clascoterone solution 7 July 2023
Slide 8: H1 2023 financial & operational highlights
02 H1 2023 financial & operational highlights 8 July 2023
Slide 9: H1 2023 revenue excluding milestones increased by 21.8% to €40.8m
H1 2023 revenue excluding milestones increased by 21.8% to €40.8m 9 July 2023
Slide 10: Business is experiencing high organic growth
Business is experiencing high organic growth Established business Two growth drivers with continues to grow increasing revenues Lialda Winlevi franchise increased by 27.7% royalty income increased by 92.3% (€16.6m in H1 2023 vs €13.0m in H1 2022) Manufacturing income decreased by 55.8% due to Cortim
Slide 11: H1 2023 achieving our plans
H1 2023 achieving our plans H1 FY23 Revenue H1 FY23 Operating profit €43.7m €7.1m H1 2022: €41.5m H1 2022: €8.1m H1 FY23 EBITDA Profit before tax €14.0m €3.7m H1 2022: €14.9m H1 2022: €9.1m 11 July 2023
Slide 12: Significant improvement in cash generation, strong financial position
Significant improvement in cash generation, strong financial position, increased stake in treasury shares H1 FY23 Net cash inflow Treasury shares held from operations at 30 June 2023 €15.5m 1,467,559 H1 2022: €12.6m 2022: 1,283,390 Cash and short-term investments at 30 June 2023 €222.1m 2022: €241.0
Slide 13: H1 2023: significant progress across product portfolio
H1 2023: significant progress across product portfolio Established portfolio Key growth drivers Pipeline Cortiment GI Genius Clascoterone solution Approval in Japan by Ferring Expanded agreement with Medtronic Phase III trial in males started June 2023 Awarded £2.5m of govt. funding for large-scale,
Slide 14: Two key growth drivers
03 Two key growth drivers 14 July 2023
Slide 15: Two revolutionary products in large markets with strong partners
Two revolutionary products in large markets with strong partners Working with top-class partners 15 July 2023
Slide 16: Winlevi: one of the most successful launches in topical acne
Winlevi®: one of the most successful launches in the topical acne space in 15 years What is Winlevi®? Acne affects an estimated 640m people worldwide The US market is worth an estimated USD 5bn p.a. Winlevi® (clascoterone) cream 1% is a prescription medicine used on the skin (topical) to treat acne
Slide 17: Winlevi: US #1 prescribed branded topical acne product
Winlevi®: US #1 prescribed branded topical acne product Prescriptions (TRX) generated Nov 2021 launched in the US by Sun Pharma on a cumulative basis to date >670,000 Strong US launch resulting in worldwide franchise 50m Patients in US Unique prescribers since launch ~15,000 Partnerships expansion (
Slide 18: Confidence raised on Winlevi performance
Confidence raised on Winlevi® performance 112 Surveyed US Dermatologists treating acne with Citi’s Research Innovation Lab 90 Average number of Acne patients treated by surveyed physicians Mr. Abhay Gandhi 12-13% Winlevi market share potential according to survey CEO (North America Business), Sun Ph
Slide 19: First-to-market GI Genius intelligent endoscopy module powered by AI
First-to-market revolutionary GI Genius™ intelligent endoscopy module powered by AI The GI GeniusTM system GI Genius™ developed by Cosmo First-to-market, deep-learning, computer-aided polyp Intelligent Medical Devices detection system Detects polyps of different shapes, sizes and morphologies in rea
Slide 20: GI Genius trial showed 50% reduction in missed colorectal polyps
GI Genius™ trial showed 50% reduction in missed colorectal polyps Total number of publications on GI Genius reached 30+ High and increasing adoption A huge market with 30,000 endoscopy of GI Genius amongst towers in the US prominent US hospitals Worldwide distribution agreement Transformational mome
Slide 21: GI Genius installed base continues to grow
GI Genius™ installed base continues to grow Launched in a number of countries, including Western Europe, US, Canada, Singapore, Australia and New Zealand 01 Beth Israel (BIDMC) Harvard, Boston 08 Einstein Medical, Pennsylvania 02 Stanford University, California 09 Hospital Corporation of America (HC
Slide 22: The genesis of genius: what makes GI Genius special
The genesis of genius: what makes GI Genius™ special Game-changing Data-based GI Genius™ was designed to assist The deep learning algorithms of the GI physicians in a truly transformative way. Genius™ module are trained on a That’s why it earned a place in the robust data-set of 13 million images of
Slide 23: Ecosystem launched to distribute new AI applications within GI Genius
Ecosystem launched to distribute new AI applications within GI Genius™ A platform with a modular architecture that hosts multiple AI algorithms Overlays AI content to all real time video flows = www.cosmoimd.com Suitable for any diagnostic/ Partnered with leading providers in clinical procedure perf
Slide 24: Platform creates opportunity to be US market leader in real-time AI
Platform creates opportunity to be US market leader in real-time AI in GI and beyond 19m 6m 500k 15m GI Upper Colonoscopy ERCP Laparoscopy endoscopy Millions of US Surgical procedures per year could benefit from real-time AI 1.6m 1.5m 640k 4m Non-GI analysis Rhinoscopy Cystoscopy Laryngoscopy Arthro
Slide 25: The economics of creating the leading medical AI platform
The economics of creating the leading medical AI platform Each 1,000 devices assuming $1,000 per app Positions Cosmo as leader in medical AI monthly Accelerates AI innovation $12M $36M $60M $180M $120M $360M ARR 3yr contract ARR 3yr ARR 3yr Improves patient outcomes contract contract Gives clinician
Slide 26: GI Genius is everywhere in the news
GI Genius™ is everywhere in the news 26 July 2023
Slide 27: GI Genius receives prestigious awards and recognition
GI Genius™ receives prestigious awards and recognition “The GI Genius intelligent Prestigious NHS AI award paves way for real-world trial of GI GeniusTM endoscopy module has the intelligent endoscopy module potential to make a world- Together with Kings College Hospital, Medtronic changing impact an
Slide 28: An exciting R&D pipeline
04 An exciting R&D pipeline 28 July 2023
Slide 29: An exciting development pipeline in pharma
An exciting development pipeline in pharma Product Indication Preclinical PH I PH II PH III One product in Phase III with Clascoterone Androgenetic alopecia high potential solution (‘AGA’) in the hair Phase III trial in males for the treatment of androgenetic alopecia started June 2023 loss market C
Slide 30: An exciting development pipeline for GI Genius
An exciting development pipeline for GI Genius™ V4 release (bowel preparation score, withdrawal time, caecum intubation) Polyp sizing 7 Automatic report applications AI support to standardize upper GI procedures under development to help the physician in the assessment of upper GI endoscopies on pat
Slide 31: Key priorities and 2023 guidance
05 Key priorities and 2023 guidance 31 July 2023
Slide 32: Our key priorities in 2023
Our key priorities in 2023 01 Guidance Expand GI Genius™ business Total Revenue 02 Expand Winlevi franchise in the RoW €110m – €120m 03 Advance clinical and development pipeline Operating Profit 04 €25m – €35m Reimburse bond in cash - no roll over 32 July 2023
Slide 33: Thank you
Mr. Alessandro Della Chà, CEO Thank you adellacha@cosmopharma.com Mr. Niall Donnelly, CFO Cosmo Pharmaceuticals N.V. ndonnelly@cosmopharma.com Riverside II Sir John Rogerson’s Quay Dublin 2, Ireland Ms. Hazel Winchester, Head of IR hwinchester@cosmopharma.com investor.relations@cosmopharma.com 33 Ju
Cosmo Pharmaceuticals — H1 2023 Earnings Presentation on 6ix